.jpg "Amedisys (NASDAQ: AMED)")
Barclays analyst Patrick Feeley maintained a Hold rating on Amedisys (AMED) today and set a price target of $120. The company’s shares opened today at $123.13.
Currently, the analyst consensus on Amedisys is a Moderate Buy with an average price target of $134.
See today’s analyst top recommended stocks >>
Based on Amedisys’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $27.46 million. In comparison, last year the company had a GAAP net loss of $3.85 million.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
